<DOC>
	<DOCNO>NCT02407210</DOCNO>
	<brief_summary>To investigate efficacy safety azilsartan compare olmesartan medoxomil patient grade I II essential hypertension</brief_summary>
	<brief_title>Efficacy Safety Azilsartan Compared Olmesartan Medoxomil Chinese Participants With Grade I II Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<criteria>1 . Both sex . eighteen year older 70 year time inform consent 2 . Grade I II essential hypertension 3 . Both sit systolic diastolic blood pressure Week 0 runin period meet follow criterion : Sitting systolic blood pressure : great equal 150 mmHg less 180 mmHg Sitting diastolic blood pressure : great equal 95 mmHg less 110 mmHg 4 . Able understand content study comply study give inform consent write participate study 1 . Secondary hypertension , grade III hypertension ( sit systolic blood pressure great equal 180 mmHg sit diastolic blood pressure great equal 110 mmHg ) , malignant hypertension，hypertensive emergencies，hypertensive urgency 2 . The following circulatoryrelated disease symptom : ( 1 ) Cardiac disease : angina pectoris ; valvular stenosis ; atrial fibrillation ; follow disease require medication : congestive heart failure arrhythmia； ( 2 ) Cerebrovascular disorder : cerebral infarction , cerebral hemorrhage ( onset within 24 week start screen period ) , transient ischemic attack ( onset attack within 24 week start screen period ) ； ( 3 ) Vascular disease : arteriosclerosis obliterans symptoms intermittent claudication； ( 4 ) Progressive hypertensive retinopathy : hemorrhage , exudation , papilledema ( observe within 24 week start screen period ) 3 . Decrease sit diastolic blood pressure 8 mmHg end runin period ( Week 0 ) compare start screen period 4 . Day/night reversal , e.g. , nightshift worker 5 . Unilateral bilateral renal artery stenosis 6 . Clinically apparent hepatic renal impairment ( e.g. , AST ALT value 2.5 x upper limit normal high , serum creatinine value 1.5 x upper limit normal high screening period ) 7 . Hyperkalemia ( laboratory value 5.5 mEq/L high runin period ) 8 . Malignant tumor 9 . Compliance study drug le 80 % runin period 10 . Poorlycontrolled diabetes mellitus ( fast plasma glucose great 11mmol/L ) ，and/or complication ( kidney disease , peripheral neuropathy ) Screening . 11 . History hypersensitivity allergy olmesartan medoxomil tablet relate drug ( ARB , ACE inhibitor , renin inhibitor ) 12 . History drug abuse ( defined illegal drug use ) alcohol dependency within 2 year start screen period 13 . Requirement exclude treatment 14 . Pregnant lactate woman 15 . Participation another clinical trial postmarketing clinical trial within 30 day start screen period 16 . Dangerous machinery operator aerial worker，motor vehicle driver</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Azilsartan，Olmesartan Medoxomil</keyword>
</DOC>